Array BioPharma licenses diabetes programme to Amgen
This article was originally published in Scrip
Executive Summary
Array BioPharma has granted Amgen exclusive worldwide rights to its small-molecule glucokinase activator programme, including the lead compound ARRY-403, which is in Phase I testing in patients with type 2 diabetes.